November 2024 Newsletter
Thank you for your continued support of the DETECT-2 study
We have many achievements to celebrate!
Recruiting site team members can review important updates and reminders regarding the study here.
These updates include:
1. Data Queries Resolution in the REDCap database
2. A reminder regarding returning study questionnaires to the central study team
3. An update on translation of the animations in the app
4. A reminder regarding the Associate PI scheme
We now have 7 sites open to recruitment!
Congratulations to the following sites for getting up and running:
Barts Health NHS Trust
Barking, Havering, and Redbridge
University Hospitals NHS Trust
Cardiff and Vale University Health Board
Imperial College Healthcare NHS Trust
University College Hospitals NHS Foundation Trust
University Hospitals Sussex NHS Foundation Trust
Nottingham University Hospitals NHS Trust
Many thanks to the 21 other sites working with us in set-up! We look forward to opening your sites in the coming months.
We are still looking for other recruiting sites to join the DETECT-2 study. Please contact us if you are interested!
Special thanks to Imperial College Healthcare NHS Trust for recruiting so well over the last few months! As a thank you, they will be receiving a sweet treat from the central study team!
Recruitment has commenced for all three cancer types (endometrial, ovarian, and colorectal cancers)
We would like to ask our sites that are open to approach their colleagues in other specialties treating patients with colorectal or gynaecological cancers to enable recruitment to all three cancer types.
Please also spread the word through your local teams, cancer networks, and research networks.
We have members from two sites enrolled in the NIHR Associate PI scheme.
We would love to support Associate PI Trainees in all our sites. We encourage interested sites to learn more about the scheme and enrol at this website.
We sincerely thank all of our team members, collaborators, supporters, funders, and (most importantly) patients involved in the DETECT-2 trial.